OverviewSuggest Edit

Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and age-related muscular degeneration (Armd). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
TypePublic
Founded2006
HQParis, FR
Websitebiophytis.com

Latest Updates

Employees (est.) (Sept 2020)21
Share Price (Sept 2020)€0.5
Cybersecurity ratingBMore

Key People/Management at Biophytis

Stanislas Veillet

Stanislas Veillet

Chairman & CEO
Pierre J. Dilda

Pierre J. Dilda

Chief Scientific Officer
Evelyne Nguyen

Evelyne Nguyen

Chief Financial Officer
Samuel Agus

Samuel Agus

Chief Medical Officer
Waly Dioh

Waly Dioh

Chief Operating Officer
Show more

Biophytis Office Locations

Biophytis has offices in Paris and Cambridge
Paris, FR (HQ)
4 Place Jussieu
Paris, FR
1 Avenue de l'Opéra
Cambridge, US
210 Broadway #201
Show all (3)

Biophytis Financials and Metrics

Biophytis Revenue

Market capitalization (23-Sept-2020)

31.6m

Closing stock price (23-Sept-2020)

0.5
Biophytis's current market capitalization is €31.6 m.
Show all financial metrics

Biophytis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Biophytis Online and Social Media Presence

Embed Graph

Biophytis News and Updates

A Biophytis recebe aprovação da ANVISA para iniciar o COVA, um estudo de fase 2/3 com o sarconeos (BIO101) para o tratamento de participantes com insuficiência respiratória relacionada à COVID-19

PARIS e CAMBRIDGE, Massachusetts, 4 de agosto de 2020 /PRNewswire/ -- A Biophytis SA (Euronext Growth Paris: ALBPS), empresa de biotecnologia de estágio clínico, especializada no desenvolvimento de possíveis medicamentos para o tratamento de doenças relacionadas à idade, inclusive doenças...

Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement

PARIS and CAMBRIDGE, Massachusetts, July 3, 2020 /PRNewswire/ -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, including neuromuscular diseases, today announced...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

PARIS and CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Biophytis S.A. (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announces the approval of all resolutions submitted to shareholders during …

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced that Daniel Schneiderman, the Company’s Chief Financial Officer bas…

Biophytis Announces Publication of its 2018 Annual Report

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced the publication of its 2018 Annual Report (Document de référence), w…

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced that it has publicly filed a registration statement with the U.S. Secur…
Show more

Biophytis Blogs

AUGUST 4, 2020

Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure.  Read the Press Release

JULY 27, 2020

Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

JULY 3, 2020

Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release

JULY 1st, 2020

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

June 11, 2020

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

June 10, 2020

Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA. Read the Press Release
Show more

Biophytis Frequently Asked Questions

  • When was Biophytis founded?

    Biophytis was founded in 2006.

  • Who are Biophytis key executives?

    Biophytis's key executives are Stanislas Veillet, Pierre J. Dilda and Evelyne Nguyen.

  • How many employees does Biophytis have?

    Biophytis has 21 employees.

  • Who are Biophytis competitors?

    Competitors of Biophytis include U.S. Stem Cell, Cannabis Sativa and Enanta Pharmaceuticals.

  • Where is Biophytis headquarters?

    Biophytis headquarters is located at 4 Place Jussieu, Paris.

  • Where are Biophytis offices?

    Biophytis has offices in Paris and Cambridge.

  • How many offices does Biophytis have?

    Biophytis has 3 offices.